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Eczema Genetics: Current State of Knowledge and
Future Goals
Sara J. Brown1 and W.H. Irwin McLean2
Multiple genetic as well as environmental factors interact in the pathogenesis of eczema. Increased
understanding of genetic predisposition in atopy and eczema has directed interest toward key pathogenic
mechanisms including skin barrier dysfunction. This review provides a succinct update on the current state of
knowledge regarding eczema genetics. We discuss the relevance of loss-of-function mutations in the filaggrin
gene within the context of other candidate gene studies and suggest possible applications for future research.
Knowledge of genetic factors in eczema may translate into a clearer understanding of pathogenic mechanisms
and hence more focused therapeutic strategies, but this remains at present a distant possibility.
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INTRODUCTION
Eczema (Johansson et al., 2004) is a
complex trait, that is, multiple genetic
and environmental factors contribute to
its pathogenesis. There is considerable
heterogeneity within the clinical phe-
notype of ‘‘eczema’’ and the disease is
also likely to encompass significant
etiological heterogeneity. The subclas-
sification of atopic and nonatopic
eczema is not clear-cut (Brown and
Reynolds, 2006) and the use of differ-
ent diagnostic criteria, focusing on
different clinical and pathological fea-
tures (Williams, 2003; Williams and
Johansson, 2005), has not facilitated a
unified understanding of eczema
pathogenesis. However, increasing
knowledge of the role of genetic pre-
disposition in atopy and eczema has
improved our understanding of this
complex trait and directed interest
toward key pathogenic mechanisms.
This review aims to provide an
update on current understanding of
the genetic basis of eczema, focusing
on atopic eczema, and to suggest
possible future research goals in this
fast-moving field.
EVIDENCE FOR A GENETIC
PREDISPOSITION IN ECZEMA
There is substantial evidence in support
of a strong genetic component in atopic
eczema. Twin studies show concor-
dance rates of 0.72–0.86 in monozygo-
tic compared with 0.21–0.23 in
dizygotic twin pairs (Larsen et al.,
1986; Schultz Larsen, 1993; Thomsen
et al., 2007) and eczema as well as
asthma and allergic rhinitis show clus-
tering within families (Kaiser, 2004).
Common features of the systemic im-
mune response link eczema with other
atopic diseases, however several lines
of investigation point to tissue-specific
genes, relating to the structure and
function of skin, as etiological factors
in eczema pathogenesis. Children
whose parents have eczema show a
higher risk of developing eczema than
children whose parents have asthma or
hay fever (Moore et al., 2004; Wadon-
da-Kabondo et al., 2004) and eczema
can occur with increased severity along
Blaschko’s lines (Hladik et al., 2005),
consistent with genetic mosaicism
(Moss, 1999). These observations sup-
port the concept that risk may be
mediated through skin-specific genes,
rather than simply through systemic
immune or ‘‘atopy’’ risk genes. Recent
thinking has focused on the importance
of epithelial barrier dysfunction in
atopic eczema, directed by evidence
from genetics as well as biochemical
and physiological studies (Cookson,
2004; Hudson, 2006; Irvine and
McLean, 2006; Jakasa et al., 2006,
2007; Taieb et al., 2006).
STRATEGIES FOR INVESTIGATING
THE GENETIC BASIS OF ATOPIC
ECZEMA
A large amount of research has been
undertaken worldwide in the search for
genetic factors in the etiology of atopy
and eczema. Three main approaches
have been used: candidate gene asso-
ciation, selecting genes for study based
on a hypothesis of known biological
function; genome-wide linkage
screens, which are hypothesis free
and compare the transmission of gene-
tic information between cases and
controls in family pedigrees; and DNA
microarray studies, which look at gene
expression in selected regions of inter-
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est, or across the whole genome. Each
of these strategies has added under-
standing to the field of eczema genet-
ics.
It is of paramount importance to
replicate previously reported findings
using different methodology, indepen-
dent population groups, and larger
sample sizes, to confirm a robust and
clinically relevant association (Hoffjan
and Epplen, 2005; Morar et al., 2006b).
Many striking preliminary discoveries
have failed to be replicated in
subsequent studies.
POINTERS FROM GENOME-WIDE
STUDIES
Genome-wide linkage screens have
been reported in families with atopic
eczema from five different populations
(Lee et al., 2000; Cookson et al., 2001;
Bradley et al., 2002; Haagerup et al.,
2004; Enomoto et al., 2007). Regions
on chromosomes 3q, 3p, 17q, and 18q
show evidence of linkage in two or
more studies, suggesting candidate sites
for eczema genes (Hoffjan and Epplen,
2005). Interestingly, only two of these
four regions have shown linkage to
asthma or other atopic disorders in
more than one study (Cookson, 2004;
Hoffjan and Epplen, 2005) indicating
that separate genes may be responsible
for eczema. Furthermore, the regions
on 1q21, 3q21, 17q25, and 20p linked
to atopic eczema overlap with known
psoriasis susceptibility loci (Cookson,
2004) although a subsequent investiga-
tion of the 17q25 locus failed to
demonstrate variants in the known
PSORS2 psoriasis locus in children
with atopic eczema (Morar et al.,
2006a). The colocalization of eczema
and psoriasis genes supports the con-
cept that tissue-specific genes influence
the eczema phenotype by control of
epidermal function, immunity, and
inflammation (Cookson, 2004). Nota-
bly, the 1q21 locus includes the epi-
dermal differentiation complex, a
dense cluster of genes including filag-
grin (FLG), involucrin, loricrin and
S100 proteins, which are involved in
the terminal differentiation of keratino-
cytes (Mischke et al., 1996).
A large-scale DNA microarray
analysis has demonstrated that four
genes encoded on 1q21 (overlying
the epidermal differentiation complex)
show different levels of expression in
eczema lesional skin compared with
controls (Sugiura et al., 2005). These
findings suggest that S100A7 and
S100A8 (showing increased expres-
sion) plus filaggrin and loricrin (show-
ing reduced expression) may be
responsible at least in part for the
epidermal barrier dysfunction that is
characteristic of atopic eczema. An-
other independent microarray analysis
has shown an increase in the expres-
sion of genes encoding CC chemokines
in eczematous skin (Nomura et al.,
2007), known to attract TH2 cells and
eosinophils. The functional signifi-
cance of these plus other genes and
partial DNA sequences identified by
DNA microarray analysis remain to be
elucidated (Saito, 2005).
CANDIDATE GENES FOR ECZEMA
AND ATOPY
Many different candidate genes have
been studied because of their theore-
tical roles in the etiology of atopic
eczema; most candidate studies have
focused on immunological mechan-
isms and several genes known to be
associated with asthma/atopy have
been investigated for linkage with
atopic eczema. At least 20 genes have
been reported as showing a statistically
significant association with eczema,
but only six associations have been
replicated in two or more independent
studies (Maintz and Novak, 2007;
Kiyohara et al., 2008). These findings
are summarized in Figure 1.
Three genes within the 5q31–33
locus show evidence of association
with atopic eczema: the cytokines
IL-4 and IL-13 and a protease inhibitor,
SPINK5 (serine protease inhibitor Kazal
type 5). Identification of mutations in
the SPINK5 gene as the cause of
Netherton syndrome (Chavanas et al.,
2000) led to the screening of this gene
for polymorphisms in patients with
atopic eczema, as Netherton syndrome
is characterized by an eczematous rash
and elevated IgE. SPINK5 encodes
lymphoepithelial Kazal type inhibitor
that is expressed in epithelial surfaces
(Komatsu et al., 2002) and it has been
suggested that lymphoepithelial Kazal
type inhibitor may provide protection
against other serine proteases that are
allergenic (Walley et al., 2001). Poly-
morphisms in SPINK5 have shown
association with atopic eczema in
cohorts from Britain and Japan (Walley
et al., 2001; Kato et al., 2003; Nishio
et al., 2003), but this association has
not been replicated in subsequent
studies (Folster-Holst et al., 2005), with
the exception of a minor parent-of-
origin effect when maternally inherited
(Weidinger et al., 2008a).
The stratum corneum chymotrypic
enzyme is involved in the proteolytic
degradation of corneodesmosomes,
regulating desquamation from the skin
surface (Ekholm et al., 2000). The
stratum corneum chymotrypic enzyme
gene has been reported as a candidate
in atopic eczema (Vasilopoulos et al.,
2004) but again this association has not
been replicated in our larger cohort
study (Weidinger et al., 2008a).
There are many other candidate
genes that showed interesting associa-
tions that have failed to be replicated
by subsequent studies. Examples in-
clude the high-affinity IgE receptor
(FCeR1-b), which showed linkage to
atopy but inconsistent findings in ecze-
ma (Coleman et al., 1993; Sandford
et al., 1993; Soderhall et al., 2001);
nucleotide-binding oligomerization do-
main proteins 1 and 2, which are
intracellular receptors for bacterial
peptides (Kabesch et al., 2003; Wei-
dinger et al., 2005a, b); and toll-like
receptor 2, which is expressed on
human keratinocytes (McInturff et al.,
2005) and recognizes pathogen-asso-
ciated molecular patterns (Ahmad-
Nejad et al., 2004; Weidinger et al.,
2006b; Merx et al., 2007). These
conflicting reports and lack of replica-
tion may result from inadequate statis-
tical power or suboptimal study design.
Careful case-definition and choice of
an appropriate, comparable control
population are important considera-
tions in genetic association studies
and large sample sizes are necessary
to detect or refute subtle but potentially
important genetic effects (Balding,
2006).
In contrast to the lack of replication
shown by many candidate genes, FLG
has now been reported to show a
strong and significant association
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with atopic eczema in more than 15
separate publications, many of which
contain a number of additional within-
study replications (Brown and Irvine,
2008; Rodriguez et al., 2008).
FILAGGRIN WITHIN THE
EPIDERMIS: A MULTIFUNCTIONAL
PROTEIN
Filaggrin (filament-aggregating protein)
has a key function in epidermal differ-
entiation and barrier function, but the
relative importance of the different
functions of filaggrin remains unclear
(Figure 2). The gene FLG encodes a
large insoluble polyprotein, profilag-
grin (Sybert et al., 1985), which
is cleaved to produce multiple filaggrin
peptides (Gan et al., 1990). Filaggrin
aggregates keratin 1, keratin 10 and
other intermediate filaments within
the cytoskeleton of keratinocytes
(Manabe et al., 1991), to bring about
their compaction during cornification,
a unique form of programmed cell
death (Candi et al., 2005). Filaggrin is
a major component of the protein–lipid
cornified cell envelope, which
forms an important permeability barrier
to water and inhibits the entry of
microbes, allergens, and irritants
(Presland et al., 2004).
Filaggrin is degraded to produce a
mixture of hygroscopic amino acids
that may contribute to epidermal bar-
rier function by retaining water and
increasing flexibility of the cornified
layer (Rawlings and Harding, 2004).
One of the most abundant amino acids
released by filaggrin proteolysis is
histidine. This is converted to trans-
urocanic acid (trans-UCA) and helps to
maintain the pH gradient of the epi-
dermis. The trans-UCA molecule un-
dergoes photoisomerization to cis-UCA
(Elias and Choi, 2005), which has local
and systemic immunosuppressive ef-
fects, demonstrated in murine models
(Noonan and De Fabo, 1992; Finlay-
Jones and Hart, 1998; Walterscheid
et al., 2006) and in human keratino-
cytes and leukocytes in vitro (Gilmour
et al., 1993; McLoone et al., 2005).
Finally, the N-terminal portion (S100
domain) of profilaggrin is a calcium-
binding domain (Presland et al., 1992,
1995; Markova et al., 1993) and may
therefore be involved in the regulation
of calcium-dependent events during
epidermal differentiation (Presland
et al., 1997).
FLG, THE STRONGEST CANDIDATE
SO FAR
In 2006, a group led by Prof Irwin
McLean (University of Dundee) re-
ported that two common loss-of-func-
tion mutations within the FLG gene
cause ichthyosis vulgaris (Smith et al.,
2006). The coexistence of ichthyosis
vulgaris and atopic eczema is well
recognized in clinical practice and
investigation of the 15 families with
ichthyosis vulgaris demonstrated a sig-
nificant association between atopic
Gene showing
association with
atopic eczema  
Locus
Interleukin-4 (IL4) 5q31−33 
(He et al., 2003;
Kawashima et al., 
1998)  
Interleukin-4 receptor
(IL4R)   
16p12.1
−11.2   
Interleukin 4 promotes the
switch to TH2 immune response
and IgE production   (He et al., 2003;
Hosomi et al., 2004;
Oiso et al., 2000)   
Interleukin-13 (IL13) 5q31−33 Interleukin 13 promotes B-cell
switch to IgE production  
(Liu et al., 2000;
Tsunemi et al., 2002)  
Mast cell chymase
(CMA1)  14q11.2 
Mast cell chymase promotes
increased microvascular
permeability and accumulation
of inflammatory cells     
(Mao et al., 1996;
Weidinger et al., 2005)
Serine protease
inhibitor kazal-type 5
(SPINK5)  
5q31 Mutations in SPINK5 gene
cause netherton syndrome  
(Kato et al., 2003;
Nishio et al., 2003;
Walley et al., 2001)  
Filaggrin (FLG) FLG null mutations causeichthyosis vulgaris  
(Palmer et al., 2006)
plus >15 other reports
reviewed in: (Brown
and Irvine, 2008;
Rodriguez et al., 2008)    
Systemic
‘atopic’
immune
response   
Epidermal
differentiation
and skin 
barrier
formation
Cutaneous
immunity,
inflammation
and infection 
1q21 
Rationale References 
Figure 1. Diagram summarising genes reported to show association with atopic eczema in two or more independent studies. The majority of research
into genetic causes of atopy and eczema originally focused on the systemic immune response, which characteristically shows a TH2 predominance and
elevated IgE levels. However, eczema and asthma do not appear to share the same genetic loci (Cookson, 2004; Hoffjan and Epplen, 2005; Veal et al., 2005)
and more recently interest has focused on skin-specific genes involved in cutaneous immunity, inflammation, and infection as well as epidermal barrier
function. Although genes may be categorized according to their primary functional site, there is clearly significant overlap and interplay between systemic
and cutaneous immunity (both innate and acquired) and the epidermal barrier that has a key function in limiting the entry of allergens and infectious agents.
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dermatitis and the two FLG null alleles,
R501X and 2282del4, with an esti-
mated LOD score (LOD to the base 10)
of 3.08–3.27 (Palmer et al., 2006). An
LOD score of X3 is considered to
indicate significant linkage and for a
complex trait this was a striking finding.
The group then proceeded to study
three additional eczema cohorts and
control populations from other sources
in Ireland, Scotland, and Denmark,
replicating the finding and showing a
strong and highly significant associa-
tion between FLG null mutations and
atopic eczema, with estimated odds
ratios of up to 13.4 (95% confidence
interval 6.2–27.5), and w2-test
P¼31017 (Palmer et al., 2006).
More than 20 loss-of-function muta-
tions within the FLG gene have now
been reported (Palmer et al., 2006;
Sandilands et al., 2006; Chen et al.,
2008; Nomura et al., 2008; Sasaki
et al., 2008; Figure 3). Five null
mutations are prevalent within the
European population, giving a com-
bined null allele frequency of 0.09,
meaning that about 9% of the well-
studied Irish population, for example,
carry one or more FLG null mutations.
This strikingly high prevalence suggests
a possible heterozygote advantage. In
this regard, a form of ‘‘natural vaccina-
tion’’ mediated by the mildly perturbed
skin barrier in heterozygotes has been
hypothesized (Sandilands et al.,
2007a, b), so that atopy may be a
modern plague that is enriched among
the survivors of ancient bacterial
plagues (Irvine and McLean, 2006).
The other rarer mutations within the
European population were identified
in families with ichthyosis vulgaris
and some may be family specific
(Sandilands et al., 2007a, b). Popula-
tion-specific mutations have also been
identified in association with ichthyosis
vulgaris and atopic eczema in Japanese
(Nomura et al., 2007, 2008; Enomoto
et al., 2008; Hamada et al., 2008) and
Singaporean Chinese populations
(Chen et al., 2008).
All the reported FLG mutations are
nonsense or frameshift mutations, each
resulting in truncation of the profi-
laggrin molecule. However, biochem-
ical and immunohistochemical studies
indicate that the truncated profilaggrin
cannot be processed into filaggrin
peptides (Sandilands et al., 2006,
2007a). Hence, even mutations occur-
ring near the 30 end of FLG result in a
similar reduction or complete absence
of filaggrin as well as a similarly severe
phenotype and with a statistically
similar effect (Brown et al., 2008c).
This equivalence of effect explains the
rationale for statistical analysis using a
‘‘combined null genotype’’ that has
been applied in most studies. This
technique groups together individuals
with any one or any combination of
two of the known FLG null mutations,
rather than analyzing each mutation
separately.
Association of the FLG null geno-
type with atopic eczema has now been
replicated in numerous case–control
studies (Marenholz et al., 2006; Palmer
et al., 2006; Ruether et al., 2006;
Barker et al., 2007; Stemmler et al.,
2007; Weidinger et al., 2007; Sandi-
lands et al., 2007b; Novak et al., 2008;
Brown et al., 2008c), as well as family
studies (Weidinger et al., 2006a; Morar
et al., 2007; Ekelund et al., 2008) and
most recently population-based studies
(Henderson et al., 2008; Brown et al.,
2008b; Weidinger et al., 2008b). Some
publications were in collaboration with
the original research group; others have
independently replicated and extended
the data. There has to date been only
one published study that did not show
an association between FLG null muta-
tions and atopic eczema (Giardina
et al., 2008). In this Italian population,
the R501X and 2282del4 mutations
occurred at a very low frequency and
screening for other reported mutations
or previously unreported Italian muta-
tions was not performed.
Given that the association of FLG
with eczema is one of the most robust
and highly significant discoveries in the
field of complex trait genetics, it is
reasonable to ask why FLG was not
detected by whole-genome linkage
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envelope  
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amino acids
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pH
dephosphorylated
and cleaved into
10-12 copies  
Diagram showing section through skin,
as seen under the light microscope   
Dermis 
Epidermis 
Keratohyalin
granules containing
profilaggrin  
 ? 
Cross-linked by
transglutaminases   
Epidermal barrier
to prevent water
loss, infection and
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Role in
calcium-
dependent
events? 
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Figure 2. Diagrammatic representation of the processing and functions of filaggrin within the
epidermis. Profilaggrin is expressed in the granular layer and is the major constituent of keratohyalin
granules that are clearly visible under the light microscope. Profilaggrin is proteolytically cleaved in the
uppermost granular cells to produce filaggrin peptides that aggregate and align keratin filaments within
the cytoskeleton of keratinocytes, helping to bring about their compaction in to a squame shape during
cornification (Candi et al., 2005). The protein–lipid cornified cell envelope, which replaces the
keratinocyte cell membrane, forms an important permeability barrier and provides mechanical defense
by maintaining skin integrity (Presland et al., 2004). Filaggrin is deiminated and degraded with a half-life
of 6 hours (Candi et al., 2005), to release hygroscopic amino acids. These may contribute to epidermal
barrier function by retaining water and are also thought to help maintain the pH gradient in healthy skin.
There is some experimental evidence that histidine, after metabolism to urocanic acid, may be involved
in UV light-induced immunosuppression (Gilmour et al. 1993; McLoone et al. 2005; Walterscheid et al.
2006). Finally, profilaggrin includes a calcium-binding domain and may therefore be involved in signal
transduction (Markova et al., 1993). Trans-UCA, trans-urocanic acid, produced by non-oxidative
deimination of histidine; cis-UCA, cis-urocanic acid produced by photoisomerization; UVB, UV B
radiation. This figure is modified from Brown and Irvine (2008) with permission from Elsevier.
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analysis? The 1q21 locus, which in-
cludes the epidermal differentiation
complex, was detected as a significant
linkage peak on one whole-genome
screen (Cookson et al., 2001). How-
ever, the whole-genome analyses re-
ported to date have each used low-
density microsattelite markers at insuf-
ficient density to detect the multiple
different FLG null mutations. The ge-
netic architecture of FLG is highly
complex; there are many low-fre-
quency null variants, each of which
will be poorly, or at best incompletely,
tagged by conventional single nucleo-
tide polymorphisms used in genome-
wide analysis, as the latter are deliber-
ately selected on the basis of high
heterozygote frequencies in the popu-
lation (Sandilands et al., 2007a, b).
Variations in case definition and use
of non-homogeneous population struc-
ture, that is, ethnically mixed study
populations, may also have been con-
founding factors.
GENOTYPE–PHENOTYPE
CORRELATION
The phenotype of early onset (before
the age of 2 years), persistent, and
severe eczema has shown the strongest
and most highly significant statistical
association with the combined FLG
null genotype, having an odds ratio of
up to 7.7 (95% confidence interval
5.3–10.9) (Barker et al., 2007;
Weidinger et al., 2007; Brown et al.,
2008c). However, the milder eczema
phenotype that is more prevalent in the
general population has also shown a
statistically significant association with
FLG null genotype in population stu-
dies (Henderson et al., 2008; Brown
et al., 2008b; Weidinger et al., 2008b).
The odds ratio for this milder pheno-
type is around 2.0, similar to the odds
ratio seen in family studies (Baurecht
et al., 2007), presumably reflecting
milder disease. In one population
study, only those children who were
homozygous for FLG null mutations
showed a statistically significant asso-
ciation with mild–moderate atopic ec-
zema (odds ratio 26.9, 95% confidence
interval 3.3–217.1), whereas the FLG
null heterozygotes did not have a
significantly increased risk of eczema
(odds ratio 1.2, 95% confidence inter-
val 0.7–1.9) suggesting a ‘‘recessive’’
type of inheritance (Brown et al.,
2008b). In ichthyosis vulgaris, the
inheritance is semidominant (that is,
the heterozygotes demonstrate a milder
phenotype than the homozygote null
mutants) (Smith et al., 2006) and in
moderate–severe eczema cases both
the FLG null heterozygotes and null
homozygotes show an increased risk of
disease (Palmer et al., 2006; Brown
et al., 2008c). The different patterns of
inheritance may perhaps be explained
by the coinheritance of genetic and
environmental risk factors in the more
severe disease phenotype.
Careful dermatological examination
can be used to help identify individuals
carrying one or more FLG null alleles.
Eczema in the context of ichthyosis
vulgaris is clearly likely to be related to
filaggrin deficiency. However the clin-
ical signs of palmar hyperlinearity
(Weidinger et al., 2006a; Novak et al.,
2008; Brown et al., 2008b) and kera-
tosis pilaris (Brown et al., 2008b) have
also each shown independent associa-
tion with FLG null mutations; further-
more, the absence of both palmar
hyperlinearity and keratosis pilaris
gives a negative predictive value of
92% (that is, 92% of children without
these features do not carry a FLG null
mutation) (Brown et al., 2008a).
The compound phenotype of asth-
ma in the context of atopic eczema has
also shown a striking association
with FLG null mutations, with esti-
mated odds ratios as high as 5.69
(95% confidence interval 2.76–11.37)
(Weidinger et al., 2007). The associa-
tion of FLG with other atopic pheno-
types is reviewed elsewhere (Rodriguez
et al., 2008).
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Q2147X 
E2422X
5′ 3
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2282del4
3702delG 
R2447X
S3247X
3321delA 
R1474X 
5360delG 7267delCA S2554X 
7945delA 
11029delCA 
11033del4 
Q3683X 
R4307X 
441delA 
1249insG 
3763delC 
Exon 1 
Encodes profilaggrin
S2889X
S3296X
Filaggrin gene
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Sequences unique to the FLG gene, encoding a S100 domain (at 5′ end of exon 3),
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Partial repeat 
Filaggrin repeat (972 bp each) 
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Figure 3. Diagrammatic representation of the filaggrin (FLG) gene showing sites of reported null
mutations. Diagram adapted from Sandilands et al. (2007a, b) and Brown and Irvine (2008) with
additional recently reported mutations in non-white populations (Chen et al., 2008; Nomura et al., 2008;
Sasaki et al., 2008). FLG is located on chromosome 1q21, within the epidermal differentiation complex,
a cluster of genes controlling the terminal differentiation of keratinocytes. Exons 1 and 2 showed no
variation between individuals with and without ichthyosis vulgaris in five families (Smith et al., 2006).
Exon 2 contains the initiation codon; exon 3 is unusually large and encodes most of the N-terminal
domain as well as all of the FLG repeats and their linker sequences. Profilaggrin is polymorphic in that
there are at least four alleles in the human population encoding 10,11, or 12 FLG repeats (Gan et al.,
1990; Sandilands et al., 2007a, b). The mutations marked in red are prevalent in the European
population, with a combined allele frequency of 0.09. The mutations marked in black are found in
European and European American populations at much lower frequencies. The mutations marked in
green have been identified in ichthyosis vulgaris and eczema cases from Chinese, Japanese, and
Singaporean Chinese populations.
www.jidonline.org 547
SJ Brown and WH Irwin McLean
Genetics of Eczema
GENETIC STUDIES IN OTHER TYPES
OF DERMATITIS
Genetic factors contributing to the
pathogenesis of nonatopic eczema and
the other forms of dermatitis (Johansson
et al., 2004) have not been extensively
investigated and are not clearly defined.
Environmental factors obviously
have an important function in the
development and perpetuation of aller-
gic as well as irritant contact dermatitis.
However, an individual variability in
susceptibility to allergic contact derma-
titis has long been recognized and
genetic factors are likely to be involved
in mediating this susceptibility (Schram
and Warshaw, 2007). Definition of a
precise phenotype of contact allergy for
the purposes of genetic research is
difficult. It has therefore been proposed
that polysensitization to contact aller-
gens (defined as sensitization to three
or more unrelated allergens) is a useful
phenotypic subgroup in which to study
genetic polymorphisms relating to con-
tact allergy-specific as well as nonspe-
cific inflammatory processes (Schnuch
et al., 2008). These authors have
reported polymorphisms in the promo-
ter regions of IL-16 and tumor necrosis
factor-a in association with the poly-
sensitized phenotype (Reich et al.,
2003; Westphal et al., 2003). In con-
trast, specific contact allergies may be
related to specific pathogenic mechan-
isms; examples include acetylation in
para-substituted arylamine-induced
contact allergy, associated with poly-
morphisms in genes encoding some
N-acetyltransferases (Westphal et al.,
2000) and the unique features of nickel
as a contact allergen (Schram and
Warshaw, 2007; Hanifin, 2008).
A polymorphism in the tumor ne-
crosis factor-a gene at position 308 has
shown association with susceptibility
to irritant contact dermatitis (Allen
et al., 2000). However, a more recent
study of cytokine gene polymorphisms
and irritant hand dermatitis found no
difference in genotype distributions
between cases and controls, although
subgroup analysis did suggest a possi-
bly increased susceptibility in indivi-
duals with the tumor necrosis factor-
a-308 polymorphism and a possible
protective effect of an IL-1a poly-
morphism (de Jongh et al., 2008a).
Theoretically, an impaired epider-
mal barrier may permit the entry of
allergens and irritants. However, the
significance of filaggrin deficiency in
allergic and/or irritant contact dermati-
tis in the absence of atopy currently
remains unclear (Lerbaek et al., 2007;
Brown and Cordell, 2008; Hanifin,
2008; Novak et al., 2008; de Jongh
et al., 2008b).
FILAGGRIN IN CONTEXT
The challenge now is to place our
understanding of the importance of
FLG null mutations in an appropriate
context within the pathogenesis of
eczema and atopy. Clearly, filaggrin
haploinsufficiency is an important and
significant component in the patho-
genesis of a proportion of eczema cases
but it cannot be used to explain the
majority of eczema, even in most of the
severe case series. Therefore, looking
objectively at the published data, what
is the significance of FLG in eczema?
Meta-analysis of nine studies has
estimated an odds ratio of 4.09 (95%
confidence interval 2.64–6.33) for
atopic eczema from case–control stu-
dies and 2.06 (95% confidence interval
1.76–2.42) from family studies, for the
combined null genotype of R501X and
2282del4 (Baurecht et al., 2007). Other
candidate genes showing somewhat
comparable odds ratios include IL-4,
odds ratio 1.88, P¼0.01 (Kawashima
et al., 1998); IL-13, odds ratio 1.7,
P¼0.03 (Liu et al., 2000) and relative
risk 2.5, P¼0.014 (He et al., 2003);
and mast cell chymase odds ratio 2.17,
P¼0.009 (Mao et al., 1996). These
significant associations have been
replicated in two or more studies and
should therefore feature alongside FLG
in our understanding of genetic predis-
position to eczema. Individuals carry-
ing mutations in more than one
candidate gene may, theoretically,
demonstrate an additive or multiplica-
tive effect; this possibility has been
investigated in one study, but signi-
ficant epistatic effects between FLG,
SPINK5, and KLK7 were not identified
(Weidinger et al., 2008a).
In the moderate–severe eczema case
series, 45.7–56% of cases carry one or
more FLG null mutations (Palmer et al.,
2006; Barker et al., 2007; Brown et al.,
2008c). However, the population attri-
butable risk fraction has been variably
estimated at between 4.2 and 15.1%
in English and German populations
(Marenholz et al., 2006; Henderson
et al., 2008; Brown et al., 2008b;
Weidinger et al., 2008b). Hence,
approximately 50% of moderate–severe
eczema cases may be attributed at least
in part to FLG null mutations, whereas
only up to 15% of mild–moderate
eczema may be explained by FLG on
a population scale. Population-level
statistics are not currently available
for other candidate genes in atopic
eczema.
Can we use this understanding of
FLG in eczema to help identify other
factors contributing to the pathogenesis
of this heterogeneous disease? Barrier
dysfunction is a characteristic feature of
eczema in lesional and non-lesional
skin (Akdis et al., 2006; Jakasa et al.,
2006, 2007) and filaggrin deficiency as
a result of FLG null mutations appears
to contribute to this feature (Kezic
et al., 2008). Examples of other genes,
as well as gene–gene and gene–envir-
onment interactions contributing to
barrier dysfunction have been demon-
strated but require further investigation.
Caspase 14, a protease involved in
keratinocyte terminal differentiation,
may contribute to epidermal barrier
dysfunction through mechanisms includ-
ing filaggrin insufficiency (Denecker
et al., 2008); FLG expression is down-
regulated in acute eczematous skin and
in keratinocytes cultured with IL-4 and
IL-13 (Howell et al., 2007) demonstrat-
ing the interplay with immunity and
inflammation; expression of profilag-
grin in human skin is reduced after
experimental barrier disruption (Torma
et al., 2007); and FLG null mutations in
combination with cat ownership at
birth may predispose to infantile ecze-
ma (Bisgaard et al., 2008), showing a
possible role for barrier dysfunction in
allergy, although surprisingly, the asso-
ciation was independent of sensitiza-
tion to cats (assessed by skin-prick
testing). A subclassification of eczema
cases into FLG-associated and FLG-
independent disease may therefore be
useful to facilitate the identification of
other genetic factors and pathogenic
mechanisms. Similarly, the role of
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environmental factors may be more
apparent and amenable to study in
eczema cases having controlled for
the presence/absence of FLG null
mutations.
FUTURE GOALS
The most urgent and attractive goal is
to translate our knowledge of genetic
predisposition into a greater under-
standing of molecular mechanisms in
the pathogenesis of eczema, to guide
the development of previously unre-
ported therapies for this common and
distressing disease. To date, identifica-
tion of the candidate genes discussed
above has not been translated into
therapeutic advances for eczema
patients. Filaggrin haploinsufficiency
has theoretical potential as a therapeu-
tic target. The wild-type allele carried
by a heterozygote might be upregu-
lated by small molecules acting on
pathways controlling FLG gene expres-
sion. In homozygous or compound
heterozygous carriers of null mutations,
molecules that enhance the cell’s
translational machinery to read through
premature termination codon muta-
tions (Ainsworth, 2005) are a possible
therapeutic avenue. The search for both
these classes of small molecules is well
underway in the McLean laboratory.
The rational design of novel ther-
apeutic interventions would be facili-
tated by a clearer understanding of
the mechanisms by which filaggrin,
its precursor, protein and breakdown
products each exert their effects
in healthy skin and eczema (Figure 2).
It is not known exactly how filaggrin
interacts with keratin filaments on a
molecular level, to bring about the
orderly collapse of keratinocytes in
the stratum corneum. The contribution
of amino acids released by filaggrin
degradation to epidermal barrier func-
tion is unclear and quantitative analysis
of barrier function may clarify this
effect. Similarly, the proposed role of
histidine in UV light-induced cuta-
neous immunosuppression requires
clarification. There are some limited
data to suggest that filaggrin repeat
number polymorphisms (the variable
number of filaggrin subunits repeated
within the profilaggrin molecule) may
be correlated with dry skin phenotype
(Ginger et al., 2005) but this study was
performed before the discovery of FLG
null mutations so the data are difficult
to interpret. It could be that copy
number variation (Redon et al., 2006)
within and around the FLG gene locus
also contributes to eczema susceptibi-
lity and it is theoretically possible that
this dose effect may even be of a similar
significance to the null mutations
themselves. Calcium is important in
the intracellular signaling pathways
of epidermal differentiation and in-
flammation. However, the function
of profilaggrin as a calcium-binding
molecule for signal transduction has
not been studied in detail.
Of relevance to clinical practice,
individuals with filaggrin insufficiency
are at increased risk of severe, persistent
eczema and future therapy may place
greater emphasis on barrier repair for
this subgroup of patients. Eczema is a
disease in which pharmacogenetics
may facilitate the development of pri-
mary prevention and treatment regimes
tailored according to the individual’s
genetic predisposition.
The technical ability to perform
more detailed, large-scale, and high-
density genome-wide association ana-
lyses has recently improved under-
standing of the genetic basis of other
complex traits, including inflammatory
bowel disease, diabetes, and breast
cancer (Wellcome Trust Case Control
Consortium, 2007). Previously unre-
ported susceptibility loci have been
identified, offering new insight into
pathogenic mechanisms in these dis-
eases (McCarthy et al., 2008); the
results of genome-wide association
studies for atopic eczema are awaited
with interest. However, current tech-
nology is still only able to assess a small
proportion of potential genetic varia-
tion (Redon et al., 2006; Stranger et al.,
2007), so a complete understanding
of individual genetic susceptibility
remains a distant possibility (McCarthy
et al., 2008; Pattin and Moore, 2008).
Large, well-designed studies with care-
ful definition of cases, appropriate
control populations, and scrupulous
attention to detail throughout the gen-
otyping process (McCarthy et al., 2008)
will be required to clarify the roles of
genetic and environmental factors in
eczema pathogenesis. Furthermore, the
enormous amount of data generated by
such comprehensive studies necessitate
rigorous analysis, with careful applica-
tion of appropriate statistical techni-
ques (Cordell and Clayton, 2005;
Balding, 2006).
In conclusion, the discovery of FLG
null mutations has been a major break-
through in understanding genetic sus-
ceptibility to atopy and eczema.
However, a very large amount of work
is still required to understand fully the
multiple interrelated genetic factors
contributing to eczema pathogenesis.
Furthermore, the potential translation
of this understanding for the benefit of
patient care represents a considerable
challenge for the future.
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